Navigation Links
Offit's Failure to Disclose Jeopardizes Swine Flu Vaccine Program
Date:9/8/2009

Doctor Who Made Millions Off MMR Manufacturer Does Not Tell Public of His Financial Relationship during NBC Dateline Broadcast

AUSTIN, Texas, Sept. 8 /PRNewswire-USNewswire/ -- As autumn approaches and millions of Americans consider taking an H1N1 Swine Flu vaccination, the integrity of all vaccine developers has been called into question by the financial relationship of a leading vaccine advocate and a pharmaceutical manufacturer. Dr. Paul Offit of Children's Hospital of Philadelphia (CHOP), who was interviewed for a Dateline NBC television special, failed to tell millions of viewers that while he was promoting MMR as safe he had also made tens of millions of dollars from selling another vaccine patent to Merck, which is the manufacturer of MMR. According to CHOP documents, Offit's share of a royalty sale for the Rotateq vaccine to Merck is a minimum of $29 million and may approach $50 million.

"When Dr. Offit went on Dateline he was probably disinclined to criticize the MMR vaccine since it is produced by the same pharmaceutical company that made him a wealthy man," said Jim Moody, attorney for the National Autism Association (NAA). "If people are to have confidence in the integrity of the Swine Flu vaccination program this fall then we need full disclosure of all financial relationships between proponents and manufacturers on every vaccine on the market. Who has an objective opinion about a company that has made them rich?"

Dateline NBC's broadcast was about the potential link between the MMR vaccine and the onset of autism. Offit has stated unequivocally that there is no connection and that he has no conflict of interest with Merck. However, he acknowledged in testimony to Congress in 2000 that "I have been in collaboration with Merck and Co. on the development of a rotavirus vaccine since 1992" and that "I am a consultant to Merck." Although the Rotateq vaccine that enriched Offit has no relationship to MMR, his close financial connections to Merck, if disclosed, are likely to affect the public's value of his opinions on the efficacy of the MMR vaccine.

"It is, at a minimum, disingenuous of Dr. Offit not to tell the public through the Dateline program what he told Congress in 2000," said Dr. Andrew Wakefield, Executive Director of Thoughtful House autism treatment center, who was also featured in the program. "Even if he is no longer a consultant to Merck, the fact the company made him wealthy by buying his rotavirus vaccine is certain to make him warmly view the company and its products, including MMR. Let us hope that all such relationships are disclosed prior to any Swine Flu vaccination program."

Offit has frequently accused Wakefield of being conflicted during his MMR research, claiming that Wakefield was being paid by a law firm for his expertise on MMR while also conducting his studies. Although physicians are frequently paid for their medical expertise in legal cases, Wakefield fully disclosed his relationship with the litigators in various UK media stories and publicly reported documents. Offit, however, has continued to back MMR as completely safe while failing to inform the public that the MMR manufacturer Merck has made him so wealthy he said "it was just like winning the lottery." As a member of the Advisory Committee on Immunization Practice, Offit also voted to include the rotavirus vaccine in the Vaccines for Children program, which ultimately made his Rotateq product worth hundreds of millions of dollars to Merck.

"Offit has zero credibility in matters of vaccine safety," said Wendy Fournier, President of the NAA. "Not only does he advance the absurd suggestion that children could safety get 100,000 vaccines at a time, he opposes any studies of the comparative health of unvaccinated children that could shed light on the extent and nature of vaccine-caused injuries, leading to their prevention.

Beyond Offit's financial conflicts, autism advocates are also dismayed about the physician's credibility on speaking about autism in general, as he does not treat patients with autism. "It's a mystery how such an inexperienced and financially conflicted man has become the go-to guy for information on autism," commented Ms. Fournier. "Here's a man with no real knowledge about autism that again and again appears in media coverage. Not only is he completely unqualified to address autism from a medical standpoint, his financial conflicts of interest disqualify him as a credible source for vaccine safety commentary as well."

    Contact:
        Wendy Fournier, NAA (Portsmouth, RI) 401.835.5828
        Jim Moody, NAA (Washington, DC) 202.246.6639


'/>"/>
SOURCE National Autism Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stuy in NEJM: New therapy prevents heart failure
2. New hope for heart failure patients
3. Why Save Bad Teeth? Dental Heroics Unnecessary and Failure Prone
4. Testosterone Therapy May Help Men With Heart Failure
5. Medication Review May Help With Heart Failure
6. Night home hemodialysis shown to be as good as transplant in treating kidney failure
7. Diabetes drug linked to increased risk of heart failure
8. Avandia Raises Heart Failure Risk More Than Actos
9. Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting
10. Hospital Care for Heart Attack, Heart Failure Patients Varies Across Nation
11. New strategies to improve treatment and ultimately prevent heart failure in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: